Fadi Alkhankan, MD
Pulmonary Disease · Huntington, WVNPI 1639383664
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,115 of the $5,479 with a category attached, or 75.1%. 28 manufacturers reported payments, led by Johnson & Johnson at 24.7% of the total. Reporting peaked in 2022 at $2,204 and has fallen 57.8% since, to $929 in 2025.
Across 194 payments — averaging $28.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- GSK$1K
- AstraZeneca$677
- Boehringer Ingelheim$433
- Insmed, Inc.$273
- Harmony Biosciences LLC$236
- plus $1K from 22 others
What the payments were for
- Travel & lodging$1,16021%
- Food & beverage$4,11575%
- Education$2044%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $1,352 |
| GSK | 54 | $1,032 |
| AstraZeneca | 22 | $677 |
| Boehringer Ingelheim | 21 | $433 |
| Insmed, Inc. | 9 | $273 |
| Harmony Biosciences LLC | 7 | $236 |
| Mylan Specialty L.p. | 10 | $173 |
| Axsome Therapeutics, Inc. | 6 | $153 |
| Actelion Pharmaceuticals US, Inc. | 4 | $134 |
| Electromed, Inc. | 10 | $129 |
| Sanofi | 6 | $119 |
| United Therapeutics Corporation | 4 | $91 |
| Amgen | 4 | $81 |
| Pulmonx Corporation | 4 | $78 |
| Baxter Healthcare | 2 | $69 |
| Verona Pharma, Inc. | 4 | $68 |
| Philips North America LLC | 3 | $61 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Grifols USA, LLC | 2 | $44 |
| ANI Pharmaceuticals, Inc. | 2 | $42 |
| Resmed Corp | 2 | $39 |
| Covis Pharma GmbH | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Merck | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Viatris Specialty LLC | 1 | $15 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$1,306
- AREXVY$241
- FASENRA$126
- Arikayce$122
How this compares
$5,479 in reported general payments places this provider in the 80th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 51 | $643,656 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 569 | $437,788 |
| Spiriva RespimatTiotropium Bromide | 139 | $89,540 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 83 | $59,153 |
| Breo ElliptaFluticasone/Vilanterol | 88 | $40,342 |
| Incruse ElliptaUmeclidinium Bromide | 96 | $38,293 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 87 | $15,549 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $15,047 |
| EliquisApixaban | 25 | $14,383 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $10,162 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $7,134 |
| Voriconazole | 19 | $5,227 |
| Wixela InhubFluticasone Propion/Salmeterol | 40 | $4,973 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $4,279 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $3,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $433 | $748,243213 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $1,032 | $526,585771 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $677 | $66,288113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Huntington
- Yousef ShweihatHuntington$6K
- Julian Lopez GarciaHuntington$5K
- Sigurdur SigurdarsonHuntington$5K
- Imran KhawajaHuntington$2K
- Amro Al-AstalHuntington$1K
- Melinda BeckerHuntington$776
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
- Maria BoustaniBeckley$95K
- Ramzi HaddadinBeckley$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.